{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T01:50:41Z","timestamp":1790819441761,"version":"4.1.0"},"reference-count":92,"publisher":"Informa UK Limited","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2006,4,30]]},"DOI":"10.2217\/14796694.2.2.169","type":"journal-article","created":{"date-parts":[[2006,3,24]],"date-time":"2006-03-24T16:09:11Z","timestamp":1143216551000},"page":"169-183","source":"Crossref","is-referenced-by-count":6,"title":["Pentostatin and Purine Analogs For Indolent Lymphoid Malignancies"],"prefix":"10.1080","volume":"2","author":[{"given":"Anthony D","family":"Ho","sequence":"first","affiliation":[{"name":"Department of Medicine V, University of Heidelberg, Im Neuenheimer Feld 410, 69120Heidelberg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manfred","family":"Hensel","sequence":"additional","affiliation":[{"name":"Department of Medicine V, University of Heidelberg, Im Neuenheimer Feld 410, 69120Heidelberg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2006,3,24]]},"reference":[{"key":"e_1_3_1_3_1_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200241020-00002"},{"key":"e_1_3_1_3_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V62.4.737.737"},{"key":"e_1_3_1_3_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/jhet.5570110438"},{"key":"e_1_3_1_3_4_1","first-page":"359","volume-title":"Biochem. Pharmacol","author":"Agarwal RP","year":"1977","unstructured":"Agarwal RP , SpectorT, ParksRE: Inhibition of adenosine deaminase by various inhibitors. Biochem. Pharmacol. 26, 359\u2013367 (1977)."},{"key":"e_1_3_1_3_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2900050103"},{"key":"e_1_3_1_3_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(72)92345-8"},{"key":"e_1_3_1_3_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(75)91950-9"},{"key":"e_1_3_1_3_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(78)80418-1"},{"key":"e_1_3_1_3_9_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.122.1.216"},{"key":"e_1_3_1_3_10_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.126.3.1003"},{"key":"e_1_3_1_3_11_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI108334"},{"key":"e_1_3_1_3_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/0145-2126(81)90106-5"},{"key":"e_1_3_1_3_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01876167"},{"key":"e_1_3_1_3_14_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.75.1.472"},{"key":"e_1_3_1_3_15_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.77.7.4292"},{"key":"e_1_3_1_3_16_1","first-page":"3451","article-title":"S-adenosylhomocysteine catabolism and basis for acquired resistance during treatment of T-cell acute lymphoblastic leukemia with 2\u00b4-deoxycoformycin alone and in combination with 9-beta-d-arabinofuranosyladenine","volume":"43","author":"Hershfield MS","year":"1983","unstructured":"Hershfield MS , KredichNM, KollerCAet al.: S-adenosylhomocysteine catabolism and basis for acquired resistance during treatment of T-cell acute lymphoblastic leukemia with 2\u00b4-deoxycoformycin alone and in combination with 9-beta-d-arabinofuranosyladenine. Cancer Res.43, 3451\u20133458 (1983).","journal-title":"Cancer Res."},{"key":"e_1_3_1_3_17_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.76.4.1998"},{"key":"e_1_3_1_3_18_1","first-page":"3343","article-title":"Phase I study of 2\u00b4-deoxycoformycin in acute lymphoblastic leukemia","volume":"41","author":"Poplack DG","year":"1981","unstructured":"Poplack DG , SallanSE, RiveraGet al.: Phase I study of 2\u00b4-deoxycoformycin in acute lymphoblastic leukemia. Cancer Res.41, 3343\u20133346 (1981).","journal-title":"Cancer Res."},{"key":"e_1_3_1_3_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(80)90060-4"},{"key":"e_1_3_1_3_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(81)91491-4"},{"key":"e_1_3_1_3_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00435411"},{"key":"e_1_3_1_3_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V57.3.406.406"},{"key":"e_1_3_1_3_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1985.3.9.1196"},{"key":"e_1_3_1_3_24_1","first-page":"130","volume-title":"Scand. J. Haematol.","author":"Spiers AS","year":"1984","unstructured":"Spiers AS , RuckdeschelJC, HortonJ: Effectiveness of pentostatin (2\u00b4-deoxycoformycin) in refractory lymphoid neoplasms. Scand. J. Haematol.32, 130\u2013134 (1984)."},{"key":"e_1_3_1_3_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/82.17.1416"},{"key":"e_1_3_1_3_26_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI111710"},{"key":"e_1_3_1_3_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V72.6.1884.1884"},{"key":"e_1_3_1_3_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(17)42718-9"},{"key":"e_1_3_1_3_29_1","first-page":"7","article-title":"Clinical pharmacokinetics of 2\u00b4-deoxycoformycin.","volume":"2","author":"Malspeis L","year":"1984","unstructured":"Malspeis L : Clinical pharmacokinetics of 2\u00b4-deoxycoformycin.Cancer Treatment Symposia2, 7\u201315 (1984).","journal-title":"Cancer Treatment Symposia"},{"key":"e_1_3_1_3_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V60.5.1096.1096"},{"key":"e_1_3_1_3_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/0145-2126(85)90094-3"},{"key":"e_1_3_1_3_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V78.10.2583.2583"},{"key":"e_1_3_1_3_33_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198401053100104"},{"key":"e_1_3_1_3_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V65.3.644.644"},{"key":"e_1_3_1_3_35_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1986.4.6.900"},{"key":"e_1_3_1_3_36_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1989.7.10.1533"},{"key":"e_1_3_1_3_37_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.4.974"},{"key":"e_1_3_1_3_38_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.1.71"},{"key":"e_1_3_1_3_39_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.05.093"},{"key":"e_1_3_1_3_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0305-7372(96)90013-4"},{"key":"e_1_3_1_3_41_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200012143432402"},{"key":"e_1_3_1_3_42_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1989.7.4.433"},{"key":"e_1_3_1_3_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)91681-5"},{"key":"e_1_3_1_3_44_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1006100900082"},{"key":"e_1_3_1_3_45_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.08.100"},{"key":"e_1_3_1_3_46_1","doi-asserted-by":"publisher","DOI":"10.1080\/1042819031000151897"},{"key":"e_1_3_1_3_47_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V104.11.339.339"},{"key":"e_1_3_1_3_48_1","doi-asserted-by":"publisher","DOI":"10.1002\/mpo.2950180307"},{"key":"e_1_3_1_3_49_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1991.9.4.565"},{"key":"e_1_3_1_3_50_1","doi-asserted-by":"publisher","DOI":"10.1159\/000227554"},{"key":"e_1_3_1_3_51_1","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2003.n.026"},{"key":"e_1_3_1_3_52_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20820"},{"key":"e_1_3_1_3_53_1","first-page":"63","article-title":"Mitoxantrone, prednisone, pentostatin, and bleomycin for patients with indolent non-Hodgkin's lymphoma relapsed or unresponsive to previous treatments. Results of a phase of a phase II study conducted by the Gruppo Italiano per lo Studio dei Linfomi (GISL)","volume":"1","author":"Federico M","year":"2003","unstructured":"Federico M , CalleaV, DanesiR, MontaniniA, Di RenzoN: Mitoxantrone, prednisone, pentostatin, and bleomycin for patients with indolent non-Hodgkin's lymphoma relapsed or unresponsive to previous treatments. Results of a phase of a phase II study conducted by the Gruppo Italiano per lo Studio dei Linfomi (GISL). Cancer Ther.1, 63\u201370 (2003).","journal-title":"Cancer Ther."},{"key":"e_1_3_1_3_54_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.144"},{"key":"e_1_3_1_3_55_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V75.10.1928.1928"},{"key":"e_1_3_1_3_56_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.1.41"},{"key":"e_1_3_1_3_57_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.9.2640"},{"key":"e_1_3_1_3_58_1","doi-asserted-by":"publisher","DOI":"10.1159\/000218466"},{"key":"e_1_3_1_3_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/0925-5710(95)00396-A"},{"key":"e_1_3_1_3_60_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428199809058373"},{"key":"e_1_3_1_3_61_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1998.01069.x"},{"key":"e_1_3_1_3_62_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199346050-00007"},{"key":"e_1_3_1_3_63_1","first-page":"546","article-title":"Response of Waldenstrom's macroglobulinemia to pentostatin (2\u00b4-deoxycoformycin)","volume":"70","author":"Riddell S","year":"1986","unstructured":"Riddell S , JohnstonJB, RaynerHL, IsraelsLG: Response of Waldenstrom's macroglobulinemia to pentostatin (2\u00b4-deoxycoformycin). Cancer Treat. Rep.70, 546\u2013548 (1986).","journal-title":"Cancer Treat. Rep."},{"key":"e_1_3_1_3_64_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V104.11.3484.3484"},{"key":"e_1_3_1_3_65_1","article-title":"Pentostatin and cylcophosphamide followed by maintenance therapy with rituximab for previously treated patients with B-cell chronic lymphocytic leukaemia, and Walendstroem's macroglobulinemia.","volume":"102","author":"Hensel M","year":"2003","unstructured":"Hensel M , KrasniqiF, VillabosM, KornackerM, HoAD: Pentostatin and cylcophosphamide followed by maintenance therapy with rituximab for previously treated patients with B-cell chronic lymphocytic leukaemia, and Walendstroem's macroglobulinemia.Blood102, 404a, (2003).","journal-title":"Blood"},{"key":"e_1_3_1_3_66_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V61.2.279.279"},{"key":"e_1_3_1_3_67_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.12.2588"},{"key":"e_1_3_1_3_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(97)80279-4"},{"key":"e_1_3_1_3_69_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008377724139"},{"key":"e_1_3_1_3_70_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.3.906.bloodjournal873906"},{"key":"e_1_3_1_3_71_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428199309149111"},{"key":"e_1_3_1_3_72_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/82.16.1353"},{"key":"e_1_3_1_3_73_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.1.257"},{"key":"e_1_3_1_3_74_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-10-3389"},{"key":"e_1_3_1_3_75_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V84.6.1765.1765"},{"key":"e_1_3_1_3_76_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V79.10.2547.bloodjournal79102547"},{"key":"e_1_3_1_3_77_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/80.10.765"},{"key":"e_1_3_1_3_78_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1989.7.2.168"},{"key":"e_1_3_1_3_79_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1991.9.2.243"},{"key":"e_1_3_1_3_80_1","first-page":"2037","article-title":"Pentostatin treatment for hairy cell leukemia patients who failed initial therapy with recombinant alpha-interferon: a report of CALGB study (8515)","volume":"8","author":"Golomb HM","year":"1994","unstructured":"Golomb HM , DodgeR, MickRet al.: Pentostatin treatment for hairy cell leukemia patients who failed initial therapy with recombinant alpha-interferon: a report of CALGB study (8515). Leukemia8, 2037\u20132040 (1994).","journal-title":"Leukemia"},{"key":"e_1_3_1_3_81_1","article-title":"Results of an open- label, pilot study of pentostain rituximab, and cyclophosphamide, in the treatment of patients with previously untreated chronic lymphocytic leukemia","author":"Reynolds C","year":"2003","unstructured":"Reynolds C , Di BellaN, DrapkinR, MuraliM, BoehmKA: Results of an open- label, pilot study of pentostain rituximab, and cyclophosphamide, in the treatment of patients with previously untreated chronic lymphocytic leukemia. Blood 102, 5155, (2003).","journal-title":"Blood"},{"key":"e_1_3_1_3_82_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2004.22.90140.6568"},{"key":"e_1_3_1_3_83_1","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2005.n.039"},{"key":"e_1_3_1_3_84_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.12.516"},{"key":"e_1_3_1_3_85_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.12.051"},{"key":"e_1_3_1_3_86_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V104.11.337.337"},{"key":"e_1_3_1_3_87_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2004.22.90140.6557"},{"key":"e_1_3_1_3_88_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1991.423"},{"key":"e_1_3_1_3_89_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.10.3117"},{"key":"e_1_3_1_3_90_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1992.10.12.1907"},{"key":"e_1_3_1_3_91_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V78.12.3269.3269"},{"key":"e_1_3_1_3_92_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/85.8.658"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/14796694.2.2.169","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:44:32Z","timestamp":1719125072000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/14796694.2.2.169"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,3,24]]},"references-count":92,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2006,4,30]]}},"alternative-id":["10.2217\/14796694.2.2.169"],"URL":"https:\/\/doi.org\/10.2217\/14796694.2.2.169","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,3,24]]}}}